MaxCyte, Inc. (AIM:MXCT)
320.00
-5.00 (-1.56%)
Feb 21, 2025, 4:35 PM GMT+1
MaxCyte Revenue
MaxCyte had revenue of $8.16M USD in the quarter ending September 30, 2024, with 2.00% growth. This brings the company's revenue in the last twelve months to $45.60M, up 19.85% year-over-year. In the year 2023, MaxCyte had annual revenue of $41.29M, down -6.72%.
Revenue (ttm)
$45.60M
Revenue Growth
+19.85%
P/S Ratio
9.82
Revenue / Employee
$318.87K
Employees
143
Market Cap
338.29M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
Dec 31, 2019 | 21.62M | 4.95M | 29.72% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Genus | 668.80M |
MaxCyte News
- 11 days ago - MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - Seeking Alpha
- 11 days ago - MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - GlobeNewsWire
- 16 days ago - MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - GlobeNewsWire
- 23 days ago - Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire
- 24 days ago - MaxCyte acquires SeQure Dx - Seeking Alpha
- 24 days ago - MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - GlobeNewsWire
- 5 weeks ago - MaxCyte estimates higher Q4 core revenue from last year - Seeking Alpha
- 5 weeks ago - MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire